公开(公告)号：WO2016074033A1

公开(公告)日：2016-05-19

申请号：PCT/AU2015/050699

申请日：2015-11-11

Applicant: THE HEART RESEARCH INSTITUTE LTD ,  THE UNIVERSITY OF MINNESOTA

Inventor： KAVURMA, Mary ,  DIBARTOLO, Belinda ,  CARTLAND, Sian ,  GRIFFITH, Thomas

IPC: A61K36/18 ,  A61K38/17 ,  A61P9/10 ,  A61P7/00 ,  A61P17/02

CPC classification number: A61K38/1866 ,  A61K38/1761 ,  A61K38/1825 ,  A61K2300/00

Abstract: Methods and compositions comprising Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) are provided for treating impaired blood flow. The compositions and methods can be used to treat, for example, ischemia and wounds.

Abstract translation: 提供包含肿瘤坏死因子（TNF）相关细胞凋亡诱导配体（TRAIL）的方法和组合物用于治疗受损的血流量。 组合物和方法可用于治疗例如缺血和创伤。

公开(公告)号：WO2001017530A1

公开(公告)日：2001-03-15

申请号：PCT/AU2000/001050

申请日：2000-09-04

Applicant: UNIVERSITY OF QUEENSLAND ,  THE HEART RESEARCH INSTITUTE LTD ,  RICHARDSON, Des ,  BERNHARDT, Paul, Vincent ,  BECKER, Erika, Michelle

Inventor： RICHARDSON, Des ,  BERNHARDT, Paul, Vincent ,  BECKER, Erika, Michelle

IPC: A61K31/4402

CPC classification number: C07D213/53 ,  A61K31/4402 ,  A61K31/4436 ,  A61K31/444 ,  C07D213/81 ,  C07D405/12

Abstract: The present invention provides 2-pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) analogues suitable for use as in vivo iron chelators, the PCIH analogue having Formula (1) wherein R 1 is an aromatic or heterocyclic group and R 2 is either H or OH; isomers thereof or salts thereof; pharmaceutical compositions containing the analogues; and uses of the analogues in the treatment of iron-overload diseases.

Abstract translation: 本发明提供适合用作体内铁螯合剂的2-吡啶基甲醛异烟酰基腙（PCIH）类似物，具有式（1）的PCIH类似物，其中R 1是芳族或杂环基团，R 2是H 或OH; 异构体或其盐; 含有类似物的药物组合物; 以及类似物在治疗铁过载疾病中的应用。

公开(公告)号：WO2020047611A1

公开(公告)日：2020-03-12

申请号：PCT/AU2019/050961

申请日：2019-09-06

Applicant: THE HEART RESEARCH INSTITUTE LTD

Inventor： WISE, Steven Garry ,  CORREIA DOS SANTOS, Miguel Angelo

IPC: B01J19/08 ,  H05H1/24 ,  C08F2/34 ,  B82Y40/00 ,  B82B3/00 ,  C08F2/46

Abstract: Plasma polymerisation apparatus is disclosed including a reaction zone and at least one gas inlet for supplying at least one monomer in a gaseous form to the reaction zone, a first electrode and a second electrode spaced apart and configured to generate an electric field in the reaction zone to form plasma polymer nanoparticulate material from the at least one monomer, a plurality of collectors configured to collect plasma-polymer nanoparticulate material formed in the reaction zone, the plurality of collectors being located adjacent the second electrode, and a cooling device located adjacent the second electrode and configured to cool the plurality of collectors. Also disclosed is plasma polymerisation apparatus that includes a confinement grid extending between a first electrode and a second electrode of the apparatus.

公开(公告)号：WO2018112543A1

公开(公告)日：2018-06-28

申请号：PCT/AU2017/051437

申请日：2017-12-21

Applicant: THE HEART RESEARCH INSTITUTE LTD

Inventor： CORREIA DOS SANTOS, Miguel Angelo ,  FILIPE, Elysse ,  LORWATTANAPONGSA, Praveesuda ,  BILEK, Marcela ,  WISE, Steven Garry

IPC: B82Y40/00 ,  B82B3/00 ,  H05H1/24 ,  C23C14/00 ,  C23C16/455 ,  C23C16/50 ,  B05D1/00 ,  C08F2/34 ,  C08F2/46 ,  C08F2/58

Abstract: This application relates to nanoparticles, including nanoparticles derived from a plasma, and their use in the formation of conjugates. The nanoparticles can be stably conjugated to a wide variety of second species, forming conjugates which can be used, for example, in therapeutic, diagnostic and experimental methods.

公开(公告)号：WO2012054988A1

公开(公告)日：2012-05-03

申请号：PCT/AU2011/001391

申请日：2011-10-28

Applicant: THE UNIVERSITY OF MELBOURNE ,  THE HEART RESEARCH INSTITUTE ,  SCHIESSER, Carl Herbert ,  STORKEY, Corin ,  DAVIES, Michael Jonathan

Inventor： SCHIESSER, Carl Herbert ,  STORKEY, Corin ,  DAVIES, Michael Jonathan

IPC: C07D345/00 ,  A61P25/28 ,  C07H5/08 ,  A61K31/33 ,  A61P35/00 ,  A61P9/10 ,  A61P39/06

CPC classification number: C07H5/08 ,  A61K31/33 ,  C07D345/00

Abstract: The present invention relates to compounds and compositions useful as antioxidants and in particular to selenium containing compounds of formula (I): wherein n is 1, 2, or 3; m is 2, 3, 4, or 5; and each R] is independently -(optionally substituted C 1 -C3 alkylene) p-OH, where p is 0 or 1, or a salt thereof. The invention also relates to the use of these seleno-compounds in the treatment of diseases or conditions associated with increased levels of oxidants produced by myeloperoxidase (MPO), such as for instance, atherosclerosis.

Abstract translation: 本发明涉及可用作抗氧化剂，特别是含有式（I）的含硒化合物的化合物和组合物：其中n为1,2或3; m为2,3,4或5; 并且每个R'独立地为 - （任选取代的C 1 -C 3亚烷基）p -OH，其中p为0或1，或其盐。 本发明还涉及这些硒化合物在治疗与由髓过氧化物酶（MPO）产生的氧化剂水平升高相关的疾病或病症的用途，例如动脉粥样硬化。

公开(公告)号：WO1992004376A1

公开(公告)日：1992-03-19

申请号：PCT/AU1991000410

申请日：1991-09-05

Applicant: THE HEART RESEARCH INSTITUTE LIMITED ,  GECZY, Carolyn ,  SIMPSON, Richard, John ,  LACKMANN, Martin

Inventor： THE HEART RESEARCH INSTITUTE LIMITED

IPC: C07K07/10

CPC classification number: C07K16/24 ,  A61K38/00 ,  C07K14/52

Abstract: The chemotactic protein CP-10, in essentially pure form, having an apparent molecular weight of approximately 10 kD and having chemotactic activity for neutrophils, monocytes/macrophages and/or other mammalian cells, or an analogue, mutant, frgment, derivative or functional homologue of CP-10. Amino acid and nucleotide sequences for CP-10 are disclosed, as well as production and use thereof.

Abstract translation: 具有约10kD的表观分子量并具有嗜中性粒细胞，单核细胞/巨噬细胞和/或其他哺乳动物细胞或类似物，突变体，片段，衍生物或功能同源物的趋化活性的基本上纯的形式的趋化性蛋白质CP-10 的CP-10。 公开了CP-10的氨基酸和核苷酸序列，以及其生产和使用。

公开(公告)号：WO2022198259A1

公开(公告)日：2022-09-29

申请号：PCT/AU2021/051134

申请日：2021-09-29

Applicant: THE HEART RESEARCH INSTITUTE LTD ,  THE UNIVERSITY OF SYDNEY

Inventor： KARIMIGALOUGAHI, Keyvan ,  CELERMAJER, David Stephen

IPC: A61K31/36 ,  A61K31/426 ,  A61K31/506 ,  A61P9/02 ,  A61P9/12

Abstract: The present disclosure relates to the field of therapeutic methods for the prevention or treatment of pre-capillary pulmonary hypertension (PH), and more particularly pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension, using β3-adrenergic receptor agonists, specifically CL316243 or mirabegron.

公开(公告)号：WO2020163906A1

公开(公告)日：2020-08-20

申请号：PCT/AU2020/050111

申请日：2020-02-11

Applicant: THE HEART RESEARCH INSTITUTE, LTD.

Inventor： WISE, Steven Garry ,  CORREIA DOS SANTOS, Miguel ,  TAN, Richard Philip ,  HUNG, Jui Chien

IPC: A61K47/58 ,  A61K47/69 ,  A61K38/20 ,  A61K31/337 ,  A61K31/192 ,  A61K31/4745 ,  A61P9/10

Abstract: The present disclosure relates to the field of nanoparticles, conjugates thereof and their use in methods of treatment or prevention of vascular inflammation. The present disclosure also relates to methods of delivering an agent to a region of a blood vessel in a patient, comprising: a) conjugating the agent to a nanoparticle to produce a conjugate; and b) delivering the conjugate to the region of the blood vessel.

公开(公告)号：WO2002043742A1

公开(公告)日：2002-06-06

申请号：PCT/AU2001/001547

申请日：2001-11-29

Applicant: THE HEART RESEARCH INSTITUTE LTD ,  KRITHARIDES, Len ,  DEAN, Roger ,  JESSUP, Wendy

Inventor： KRITHARIDES, Len ,  DEAN, Roger ,  JESSUP, Wendy

IPC: A61K31/724

CPC classification number: A61K45/06 ,  A61K31/685 ,  A61K31/714 ,  A61K31/724 ,  A61K2300/00

Abstract: The invention provides a method of depleting human monocytes of cholesterol, cholesteryl esters, 7-ketocholesterol and 7-ketocholesteryl esters by treating the human monocytes with a cyclodextrin having a low cholesterol affinity together with phospholipid vesicles.

Abstract translation: 本发明提供了通过用低胆固醇亲和力的环糊精与磷脂囊泡一起处理人单核细胞来消耗胆固醇，胆固醇酯，7-酮胆固醇和7-酮胆固醇酯的人单核细胞的方法。

公开(公告)号：WO2010000011A1

公开(公告)日：2010-01-07

申请号：PCT/AU2008/000993

申请日：2008-07-04

Applicant: THE HEART RESEARCH INSTITUTE LTD ,  SIEVEKING, Daniel, Peter ,  NG, Martin, Kean, Chong

Inventor： SIEVEKING, Daniel, Peter ,  NG, Martin, Kean, Chong

IPC: A61K31/568 ,  A61K31/56 ,  A61K31/5685 ,  A61P5/26 ,  A61P9/10

CPC classification number: A61K31/56 ,  A61K31/568 ,  A61K31/5685

Abstract: The present invention relates to the field of therapy and prophylaxis of vascular tissue damage and/or complications and/or disease of vascular tissue by vascular regeneration and endothelium repair. The inventors have found that administration of an androgen receptor agonist alleviates one or more adverse vascular diseases and/or vascular complications thereof or adverse effects of androgen deficiency, with implications for prophylactic and therapeutic interventions.

Abstract translation: 本发明涉及通过血管再生和内皮修复治疗和预防血管组织损伤和/或并发症和/或血管组织疾病的领域。 本发明人已经发现，施用雄激素受体激动剂可缓解一种或多种不利的血管疾病和/或其血管并发症或雄激素缺乏的不利影响，对预防和治疗干预的影响。